VFA
GTHX

Valeo Financial Advisors’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

Valeo Financial Advisors’s Portfolio GTHX Stock Details GTHX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-10,646
Closed -$234K – 629
2021
Q2 		$234K Buy
10,646
+10,100
+1,850% +$224K 0.01% 415
2021
Q1 		$13K Sell
546
-454
-45% -$10.6K ﹤0.01% 1300
2020
Q4 		$18K Buy
+1,000
New +$14.9K ﹤0.01% 1056

Other funds holding GTHX

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Valeo Financial Advisors's GTHX Position: Q3 2021 in Review

Valeo Financial Advisors sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q3 2021, closing a stake of 10,646 shares — an estimated $234K sold.

Valeo Financial Advisors first reported a position in GTHX in Q4 2020 and held it in 3 quarters. The position peaked at $234K in Q2 2021. 115 funds tracked by Wall St. Rank hold GTHX as of Q3 2021.

  • Valeo Financial Advisors reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • Valeo Financial Advisors sold 10,646 G1 Therapeutics, Inc. Common Stock shares in Q3 2021, an estimated $234K.
  • Valeo Financial Advisors first reported a position in G1 Therapeutics, Inc. Common Stock in Q4 2020 and held it in 3 quarters.
  • Valeo Financial Advisors's G1 Therapeutics, Inc. Common Stock position peaked at $234K in Q2 2021.
  • 115 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q3 2021.

Based on Valeo Financial Advisors's 13F filing for Q3 2021, filed 2 Nov 2021.